/

Amgen Inc.

AMGN US

AMGN USAmgen Inc.

United States Composite

271.91

USD

+2.98

(+1.11%)

12.49EPS Dil.

21.65P/E

145.58BMarket Cap

3.13%Div. Yield

Next Earnings

April 25

Ex-Dividend Date

May 16

Dividend Date

June 7

Held by Insiders

0.25%

Held by Institutions

80.89%

Short % of Float

2.06%

YTD Yield

12.53%

3Y Yield

6.77%

5Y Yield

52.66%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

2,167

1,428

1,443

LT Borrowings

59,377

59,040

63,170

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

535

Market Capitalization

118,758

143,813

154,206

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

47,380

48,477

30,332

Cash, Cash Equivalents & STI

34,248

34,741

10,944

Accounts Receivable, Net

5,830

6,145

7,268

Inventories

4,978

5,026

9,518

Total Current Liabilities

17,097

16,954

18,392

Payables & Accruals

14,930

15,526

15,568

ST Debt

2,167

1,428

1,443

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

4.26%

3.56%

7.09%

Net Income, GAAP

27.80%

-3.82%

2.52%

Free Cash Flow

4.20%

-5.99%

-16.23%

Total Cash Common Dividend

12.89%

5.42%

8.58%

Total Equity

-6.33%

-5.85%

70.23%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

5,901

6,526

6,706

6,846

25,979

2022

6,238

6,594

6,652

6,839

26,323

2023

6,105

6,986

6,903

8,196

28,190

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

2.85

0.81

3.32

3.37

10.34

2022

2.69

2.46

4.01

3.02

12.18

2023

5.32

2.58

3.23

1.43

12.56

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

1.76

7.04

2022

1.97

1.94

7.80

2023

2.13

8.52

Company Description

CEO: Mr. Robert A. Bradway
Full Time Employees: 26,700
Sector: Healthcare
Industry: Drug Manufacturers - General
Address: One Amgen Center Drive Thousand Oaks CA United States 91320-1799
IPO Date: Jun 17, 1983
CIK: 0000318154
Website: www.amgen.com
Business: Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Company News

Zacks
20 days ago
Here's Why Amgen (AMGN) Stock is Outperforming the Industry
Yahoo
20 days ago
Here's Why Amgen (AMGN) Stock is Outperforming the Industry
Tipranks
20 days ago
Analysts’ Top Healthcare Picks: Amgen (AMGN), Intra-Cellular Therapies (ITCI)
Reuters
21 days ago
US takes next step in Medicare drug price negotiations with pharma companies
Zacks
22 days ago
Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Yahoo
22 days ago
Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Yahoo
22 days ago
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
Zacks
22 days ago
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
Zacks
22 days ago
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
Zacks
22 days ago
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Zacks
25 days ago
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Yahoo
25 days ago
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Biopharmadive
25 days ago
Bristol Myers says KRAS drug succeeds in key trial
Yahoo
a month ago
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Zacks
a month ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Zacks
a month ago
Should You Invest in the iShares Biotechnology ETF (IBB)?
Yahoo
a month ago
3 Biotech Stocks to Buy on the Dip: March 2024
Zacks
a month ago
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
Yahoo
a month ago
7 Dow Stocks to Buy on the Dip: March 2024
Zacks
a month ago
Wall Street Awaits Consumer Confidence Data

Company Description

CEO: Mr. Robert A. Bradway
Full Time Employees: 26,700
Sector: Healthcare
Industry: Drug Manufacturers - General
Address: One Amgen Center Drive Thousand Oaks CA United States 91320-1799
IPO Date: Jun 17, 1983
CIK: 0000318154
Website: www.amgen.com
Business: Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Company News

Zacks
20 days ago
Here's Why Amgen (AMGN) Stock is Outperforming the Industry
Yahoo
20 days ago
Here's Why Amgen (AMGN) Stock is Outperforming the Industry
Tipranks
20 days ago
Analysts’ Top Healthcare Picks: Amgen (AMGN), Intra-Cellular Therapies (ITCI)
Reuters
21 days ago
US takes next step in Medicare drug price negotiations with pharma companies
Zacks
22 days ago
Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Yahoo
22 days ago
Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Yahoo
22 days ago
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
Zacks
22 days ago
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
Zacks
22 days ago
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
Zacks
22 days ago
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Zacks
25 days ago
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Yahoo
25 days ago
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Biopharmadive
25 days ago
Bristol Myers says KRAS drug succeeds in key trial
Yahoo
a month ago
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Zacks
a month ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Zacks
a month ago
Should You Invest in the iShares Biotechnology ETF (IBB)?
Yahoo
a month ago
3 Biotech Stocks to Buy on the Dip: March 2024
Zacks
a month ago
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
Yahoo
a month ago
7 Dow Stocks to Buy on the Dip: March 2024
Zacks
a month ago
Wall Street Awaits Consumer Confidence Data